SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02196)
INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED 30 JUNE 2017
The board (the ''Board'') of directors (the ''Directors'') of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') is pleased to announce the unaudited interim results of the Company and its subsidiaries (collectively, the ''Group'') for the six months ended 30 June 2017 (the ''Reporting Period'').
FINANCIAL HIGHLIGHTS
Interim Condensed Consolidated Statement of Profit or Loss
Six months ended 30 June 2017
Six months ended 30 June 2017 2016
Notes | RMB'000 (Unaudited) | RMB'000 (Unaudited) | |
REVENUE | 3 | 8,276,941 | 6,877,865 |
Cost of sales | (3,571,893) | (3,228,575) | |
Gross profit | 4,705,048 | 3,649,290 | |
Other income | 4 | 70,484 | 85,548 |
Selling and distribution expenses | (2,283,045) | (1,679,761) | |
Administrative expenses | (783,911) | (663,711) | |
Research and development expenses | (461,320) | (307,236) | |
Other gains | 5 | 491,900 | 375,268 |
Other expenses | (80,319) | (48,344) | |
Interest income | 33,969 | 35,973 | |
Finance costs Share of profits and losses of: Joint ventures | 7 | (268,021) (6,061) | (234,453) 868 |
Associates | 760,440 | 716,328 | |
PROFIT BEFORE TAX | 6 | 2,179,164 | 1,929,770 |
Income tax expense | 8 | (252,545) | (181,145) |
PROFIT FOR THE PERIOD | 1 ,926,619 | 1,748,625 | |
Attributable to: Owners of the parent | 1,689,060 | 1,500,266 | |
Non-controlling interests | 237,559 | 248,359 | |
1,926,619 | 1,748,625 | ||
EARNINGS PER SHARE |
ATTRIBUTABLE TO ORDINARY
EQUITY HOLDERS OF THE PARENT 9
Basic RMB0.70 RMB0.65
Diluted RMB0.70 RMB0.65
Interim Condensed Consolidated Statement of Comprehensive Income
Six months ended 30 June 2017
Six months ended 30 June 2017 2016
RMB'000 RMB'000
(Unaudited) (Unaudited)
PROFIT FOR THE PERIOD 1 ,926,619 1,748,625
OTHER COMPREHENSIVE INCOME
Other comprehensive income to be reclassified to profit or loss in subsequent periods:
Available-for-sale investments: Changes in fair value | (25,350) | (69,921) |
Reclassification adjustments for gains included in the | ||
consolidated statement of profit or loss | ||
- Gain on disposal | (123,164) | (95,637) |
Income tax effect | 13,042 | 39,465 |
(135,472) | (126,093) | |
Share of other comprehensive (loss)/income of associates | (30,360) | 58,732 |
Exchange differences on translation of foreign operations | (5,816) | (10,841) |
Other comprehensive income not being reclassified to | ||
profit or loss in subsequent periods OTHER COMPREHENSIVE LOSS FOR THE PERIOD, | - | - |
NET OF TAX | (171,648) | (78,202) |
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD | 1 ,754,971 | 1,670,423 |
Attributable to: | ||
Owners of the parent | 1,528,993 | 1,419,695 |
Non-controlling interests | 225,978 | 250,728 |
1,754,971 | 1,670,423 |
Interim Condensed Consolidated Statement of Financial Position
30 June 2017
Notes | 30 June 2017 RMB'000 | 31 December 2016 RMB'000 | |
(Unaudited) | (Audited) | ||
NON-CURRENT ASSETS | |||
Property, plant and equipment | 6,607,398 | 6,325,479 | |
Prepaid land lease payments | 1,325,452 | 1,030,485 | |
Goodwill | 3,817,274 | 3,473,110 | |
Other intangible assets | 2,876,918 | 2,620,078 | |
Investments in joint ventures | 655,969 | 248,421 | |
Investments in associates | 17,029,992 | 15,870,262 | |
Available-for-sale investments | 2,675,805 | 2,674,436 | |
Deferred tax assets | 142,405 | 129,551 | |
Other non-current assets | 347,699 | 574,771 | |
Total non-current assets | 35,478,912 | 32,946,593 | |
CURRENT ASSETS | |||
Inventories | 1,965,661 | 1,670,738 | |
Trade and bills receivables | 10 | 2,963,608 | 2,389,862 |
Prepayments, deposits and other receivables | 696,793 | 659,188 | |
An equity investment at fair value through profit or loss | 27,094 | 48,489 | |
Cash and bank balances | 9,445,010 | 5,996,030 | |
Total current assets | 15,098,166 | 10,764,307 |
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 29 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 29 August 2017 15:42:05 UTC.
Original documenthttp://www.fosunpharma.com/uploads/20170829112841.pdf
Public permalinkhttp://www.publicnow.com/view/CD008F5323A626072981CC03239332646A07F4DA
